KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Long-Term Investments (2016 - 2025)

AbbVie (ABBV) has disclosed Long-Term Investments for 14 consecutive years, with $268.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 3.94% to $268.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $268.0 million, a 3.94% decrease, with the full-year FY2025 number at $268.0 million, down 3.94% from a year prior.
  • Long-Term Investments was $268.0 million for Q4 2025 at AbbVie, down from $291.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $310.0 million in Q2 2025 to a low of $235.0 million in Q3 2022.
  • A 5-year average of $275.2 million and a median of $273.5 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: surged 291.03% in 2021, then dropped 14.75% in 2022.
  • AbbVie's Long-Term Investments stood at $277.0 million in 2021, then decreased by 13.0% to $241.0 million in 2022, then grew by 26.14% to $304.0 million in 2023, then fell by 8.22% to $279.0 million in 2024, then decreased by 3.94% to $268.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Long-Term Investments are $268.0 million (Q4 2025), $291.0 million (Q3 2025), and $310.0 million (Q2 2025).